P-glycoprotein inhibition leads to enhanced disruptive effects by anti-microtubule cytostatics at the in vitro blood-brain barrier.
- 1 January 2001
- journal article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 18 (5), 587-592
- https://doi.org/10.1023/a:1011016923346
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Establishment and functional characterization of an in vitro model of the blood–brain barrier, comprising a co-culture of brain capillary endothelial cells and astrocytesEuropean Journal of Pharmaceutical Sciences, 2001
- Role of blood‐brain barrier P‐glycoprotein in limiting brain accumulation and sedative side‐effects of asimadoline, a peripherally acting analgaesic drugBritish Journal of Pharmacology, 1999
- Approaches to multidrug resistance reversalExpert Opinion on Investigational Drugs, 1998
- The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.Journal of Clinical Investigation, 1998
- Understanding and controlling the cell cycle with natural productsChemistry & Biology, 1996
- Role of the endothelial cytoskeleton in blood-brain-barrier permeability to proteinActa Neuropathologica, 1995
- Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.Journal of Clinical Investigation, 1995
- Microtubule dynamics: taking aim at a moving targetChemistry & Biology, 1995
- Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites.Proceedings of the National Academy of Sciences, 1989
- Cell Surface P-Glycoprotein Associated with Multidrug Resistance in Mammalian Cell LinesScience, 1983